ArticleFrontiers in immunology2026
A 76-week real-world multidimensional analysis of guselkumab in moderate to severe plaque psoriasis: a retrospective cohort study based on Chinese clinical practice standards.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Guselkumab, a monoclonal antibody targeting IL-23p19, has shown durable efficacy and safety in global phase III trials and real-world studies. However, in Chinese populations, comprehensive real-world evidence regarding its effects across disease severities, body areas, and metabolic parameters remains limited. Objective: To conduct a multidimensional evaluation of guselkumab in moderate to severe plaque psoriasis based on Chinese clinical practice standards. Methods: This retrospective analysis enrolled 90 patients receiving guselkumab and assessed efficacy from multiple dimensions, along with adverse events, drug survival, and metabolic indicators. Composite indices were used to evaluate coronary artery disease (CAD) and insulin resistance risk. Results: Guselkumab showed sustained efficacy over 76 weeks in Chinese patients. Body area analysis showed significantly faster clearance of head lesions, with 40.0% of patients achieving complete clearance at week 4, compared to only 16.0% for lower extremities ( Conclusion: This study confirms the durable efficacy and safety of guselkumab in Chinese patients with plaque psoriasis, with early response heterogeneity favoring the head. Treatment did not increase CAD or insulin resistance risk. Normal BMI and biologic-naïve status were associated with superior efficacy, supporting precision management strategies that integrate cutaneous and systemic monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.